

1 **Rethinking immunologic risk: a retrospective cohort study of severe SARS-CoV-2 infections in**
2 **individuals with congenital immunodeficiencies**

3
4 Alan A. Nguyen*, Saddiq B. Habiballah*[†], Brenna LaBere*, Megan Day-Lewis, Megan Elkins, Amer Al-
5 Musa, Anne Chu, Jennifer Jones, Ari J. Fried, Douglas McDonald, David P. Hoytema van Konijnenburg,
6 Shira Rockowitz, Piotr Sliz, Hans C. Oettgen, Lynda C. Schneider, Andrew MacGinnitie, Lisa M.
7 Bartnikas, Craig D. Platt, Toshiro K. Ohsumi[‡], Janet Chou[‡]

8
9 *A. A. Nguyen, S. B. Habiballah, and B. LaBere contributed equally

10 [‡]T. K. Ohsumi and J. Chou contributed equally

11
12 **Affiliations:** Division of Immunology, Boston Children’s Hospital and Harvard Medical School, Boston,
13 Massachusetts (A.A.N, S.B.H., B.L., M.D-L., M.E., A.A., A.C., J.J., A.J.F., D.M., D.H., H.C.O., L.C.S.,
14 A.M., L.B., C.D.P., J.C); Research Computing, Information Technology, Boston Children’s Hospital,
15 Boston, MA (S.R., P.S.); The Manton Center for Orphan Disease Research, Boston Children’s Hospital,
16 Boston, Massachusetts (S.R., P.S.); Division of Molecular Medicine, Boston Children’s Hospital, Boston,
17 Massachusetts (P.S.); Be Biopharma, Boston, Massachusetts (T.K.O.)

18 [†]Current affiliation: Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
19 KSA (S.B.H)

20
21 **Disclosures:** No authors have disclosures relevant to the content of this manuscript.

22 **Corresponding author:** Janet Chou, MD, Boston Children’s Hospital, 300 Longwood Avenue, Boston,
23 MA 02115; email: Janet.Chou@childrens.harvard.edu

25 **Abstract**

26 **Background.** Debates on the allocation of medical resources during the COVID-19 pandemic revealed
27 the need for a better understanding of immunologic risk. Studies highlighted variable clinical outcomes of
28 SARS-CoV-2 infections in individuals with defects in both adaptive and innate immunity, suggesting
29 additional contributions from other factors. Notably, none of these studies controlled for variables linked
30 with social determinants of health.

31 **Objective.** To determine the contributions of determinants of health to risk of hospitalization for SARS-
32 CoV-2 infection among individuals with inborn errors of immunodeficiencies.

33 **Methods.** This is a retrospective, single-center cohort study of 166 individuals with inborn errors of
34 immunity, aged two months through 69 years, who developed SARS-CoV-2 infections from March 1,
35 2020 through March 31, 2022. Risks of hospitalization was assessed using a multivariable logistic
36 regression analysis.

37 **Results.** The risk of SARS-CoV-2-related hospitalization was associated with underrepresented racial and
38 ethnic populations (odds ratio [OR] 5.29; confidence interval [CI], 1.76-17.0), a diagnosis of any
39 genetically-defined immunodeficiency (OR 4.62; CI, 1.60-14.8), use of B cell depleting therapy within
40 one year of infection (OR 6.1; CI, 1.05-38.5), obesity (OR 3.74; CI, 1.17-12.5), and neurologic disease
41 (OR 5.38; CI, 1.61-17.8). COVID-19 vaccination was associated with reduced hospitalization risk (OR
42 0.52; CI, 0.31-0.81). Defective T cell function, immune-mediated organ dysfunction, and social
43 vulnerability were not associated with increased risk of hospitalization after controlling for covariates.

44 **Conclusions.** The associations between race, ethnicity, and obesity with increased risk of hospitalization
45 for SARS-CoV-2 infection indicate the importance of variables linked with social determinants of health
46 as immunologic risk factors for individuals with inborn errors of immunity.

47

48 **Highlights:**

- 49 1. *What is already known about this topic?* Outcomes of SARS-CoV-2 infections in individuals
50 with inborn errors of immunity (IEI) are highly variable. Prior studies of patients with IEI have
51 not controlled for race or social vulnerability.
- 52 2. *What does this article add to our knowledge?* For individuals with IEI, hospitalizations for
53 SARS-CoV-2 were associated with race, ethnicity, obesity, and neurologic disease. Specific types
54 of immunodeficiency, organ dysfunction, and social vulnerability were not associated with
55 increased risk of hospitalization.
- 56 3. *How does this study impact current management guidelines?* Current guidelines for the
57 management of IEIs focus on risk conferred by genetic and cellular mechanisms. This study
58 highlights the importance of considering variables linked with social determinants of health and
59 common comorbidities as immunologic risk factors.

60

61 **Key Words:** SARS-CoV-2, COVID-19, health disparities, primary immunodeficiency, inborn errors of
62 immunity

63 **Abbreviations:** CI, confidence interval; COVID-19, Coronavirus disease 2019; IEI, inborn errors of
64 immunity; OR, odds ratio; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; SDOH, social
65 determinants of health; SVI: social vulnerability index.

66

67

68

69 **Introduction**

70 The COVID-19 pandemic prompted dilemmas and debates regarding the allocation of medical
71 resources.¹⁻³ These debates highlighted a critical gap in medicine that remains today: the paucity of
72 established measures of immunologic risk. This contrasts with the extensive framework of risk
73 assessment that is the bedrock of preventative medicine. The United States Department of Health and
74 Human Services Healthy People 2030 screening recommendations include assessments for cardiovascular
75 disease, osteoporosis, cancer, sexually transmitted diseases, mental health, diabetes, child development,
76 pregnancy, and sensory or communication disorders⁴. While these recommendations were developed pre-
77 pandemic, COVID-19 has heightened the importance of screening for immunologic risk which is notably
78 absent.

79 Current knowledge of immunologic risk is largely derived from clinical outcomes of primary or
80 secondary immunodeficiencies. Primary immunodeficiencies, commonly referred to as inborn errors of
81 immunity, consist of 485 disorders caused by defects in genes important for host immunity.⁵ Studies have
82 identified cellular and molecular mechanisms of susceptibility to SARS-CoV-2 among the four main
83 types of inborn errors of immunity: (1) combined immunodeficiencies with diminished T and B cell
84 function, (2) humoral immunodeficiencies impairing B cell function, (3) defective innate immunity
85 affecting innate immune cells or signaling, and (4) primary immune regulatory disorders with
86 autoimmunity as the dominant feature (**Figure 1A**).^{6,7} In the U.S., national guidelines for prioritizing anti-
87 SARS-CoV-2 therapies highlighted defective T cell function as a high risk condition due to the
88 established role of T cells in orchestrating serologic immunity and eradicating virus-infected cells.⁸
89 Surprisingly, patients with severe combined immunodeficiency exhibited a spectrum of outcomes with
90 SARS-CoV-2 infections, ranging from mild to fatal. In addition to highlighting the importance of innate
91 immunity, multiple studies revealed conflicting outcomes of SARS-CoV-2 infections in individuals with
92 other types of inborn errors of immunity,^{6,9-22} suggesting additional risk factors beyond mechanistically-
93 defined immune defects. As these studies were predominantly comprised of adults and few included
94 multivariate analyses, the relative contributions of age, comorbidities, and immunologic defects were not

95 delineated. None of these studies controlled for race, Hispanic ethnicity, or social vulnerability. Thus, the
96 relative contributions of molecular risk factors compared to socioeconomic disparities to SARS-CoV-2
97 infection outcomes remain unknown.

98 We hypothesized that general risk factors and variables associated with health disparities such as
99 race and ethnicity correlate with increased immunologic risk, even in a population with mechanistically
100 defined immunodeficiencies. We performed a two-year retrospective cohort study of 166 patients with
101 inborn errors of immunity, aged two months through 69 years of age. Of published studies to date, this is
102 the largest and longest study of outcomes from SARS-CoV-2 infections in patients with inborn errors of
103 immunity.

104

105 **Methods**

106 *Study design and setting.* This is a retrospective, single-center cohort study at Boston Children's
107 Hospital. As one of the nation's largest clinical immunology programs, the Division of Immunology
108 provides longitudinal outpatient care for patients with inborn errors of immunity ranging from the
109 neonatal period through 75 years of age and inpatient care for individuals until the age of 35 years.
110 Hospitalization for those older than 35 years is coordinated at adult hospitals. Patients in our cohort had a
111 median follow-up of 9.1 years in our immunology clinic. This study was approved by the Boston
112 Children's Hospital Institutional Review Board.

113 *Study objectives, variables, and outcome.* We aimed to determine factors associated with severe
114 SARS-CoV-2 infections in patients with inborn errors of immunity, with hospitalizations as the primary
115 outcome. Data were abstracted from the Boston Children's Hospital electronic medical record by clinical
116 immunologists using a standardized data collection instrument. To reduce bias inherent in a retrospective
117 study, variables were defined prior to study initiation: age, race, ethnicity, social vulnerability index
118 (SVI), past medical history, and history of vaccinations and therapeutics against SARS-CoV-2. Race and
119 ethnicity were classified based on patient self-report in the electronic medical record. Patient zip codes
120 were matched to census tracts for determination of SVI.²³ For zip codes contained within multiple census

121 tracts, a weighted average SVI was calculated using the American Community Survey 2014–2018
122 population estimates.²⁴ Defective T cell function was defined as 30% of normal PHA proliferation and/or
123 history of opportunistic infections indicative of impaired T cell function²⁵. We identified patients with
124 organ dysfunction, as defined by: (1) histological evidence of immune cell infiltration in organs, or (2)
125 laboratory or otherwise measurable evidence of impaired organ function attributed by the patient's
126 primary immunologist to recurrent infections, autoimmunity, or chronic inflammation. Organ dysfunction
127 criteria were met prior to COVID-19 infections. Obesity was defined based on CDC definitions of weight
128 classification: in patients under 20 years of age, BMI at the 95th percentile or higher was used; in patients
129 over 20 years of age, BMI of 30 or greater was used. Reasons for hospitalization were determined by
130 chart review, as specified by the admission note. Respiratory insufficiency was defined as increased work
131 of breathing, hypoxia, or respiratory failure. Hemodynamic instability was defined as unstable or low
132 blood pressure requiring intervention. Worsening immune dysregulation was defined as evidence of
133 active disease-specific organ dysfunction or cytopenias. Fever and neutropenia were defined as
134 temperatures >38C and absolute neutrophil count <500 cells/microliter. Severe gastrointestinal symptoms
135 included vomiting and/or diarrhea causing electrolyte derangements and/or hypotension requiring
136 intervention. Clinical monitoring due to clinician concern was dependent on physician concern related to
137 the patient's baseline health status, diagnosis, and perceived risk in the setting of acute SARS CoV-2.

138 *Patients.* Patients eligible for this study had (1) a diagnosis of an inborn error of immunity and (2)
139 positive nucleic acid amplification test or antigen test for SARS-CoV-2 infection between March 15,
140 2020 through March 31, 2022 (**Figure 1B**). Specifically, patients with inborn errors of immunity were
141 first identified by an ICD-10 code (**Figure E2**) used for a clinical visit between January 1, 2015 and
142 January 1, 2020, which was verified through a medical record review by this study's clinical immunology
143 team. Patients with positive testing for SARS-CoV-2 were identified through review of: (1) SARS-CoV-2
144 testing results available at Boston Children's Hospital, (2) referrals for SARS-CoV-2 therapeutics, (3) and
145 medical records. Patients were not eligible if they had a secondary or acquired immunodeficiency. There

146 were no inpatients incidentally found to have positive SARS-CoV-2 RT-PCR while hospitalized for
147 diagnoses unrelated to COVID-19.

148 *Statistical analyses.* We used a multivariable logistic analysis to identify potential risk factors for
149 hospitalization due to SARS-CoV-2. Variance inflation factors were used to assess multicollinearity of
150 potential covariates²⁶. Since hospitalization for acute SARS-CoV-2 infections are relatively rare until the
151 sixth decade of life²⁷, we performed the logistic regression with penalized likelihood to reduce the bias
152 inherent in small sample sizes²⁸. As a confirmatory approach, we also identified risk factors for
153 hospitalization using a standard logistic regression model with the same variables. There was no missing
154 data in this data set. Statistical analyses were performed with Statistical Package for the Social Science
155 (SPSS, version 27.0 software) and R Statistical Software (version 4.1.3).

156 *Role of the funding source.* The funding source had no role in the design, execution, analysis, or
157 reporting of this study.

158

159 **Results**

160 *Patient Characteristics*

161 Among 2513 patients with a confirmed diagnosis of an inborn error of immunity, 166 had at least
162 one SARS-CoV-2 infection during the study period (**Figure 1B**). Thirty-one patients were hospitalized
163 (**Table 1**), most commonly for respiratory failure (**Table 2**). Twelve patients required critical care and
164 one died. The median age of inpatients was 16.3 years (range 0.5 – 51.7 years), compared with 14.9 years
165 for outpatients (range 0.2 – 68.8 years). The percentage of hospitalized patients (18.7%, with a median
166 age of 16.3 years) is higher than that of the general pediatric and adolescent population, which has been
167 estimated to be less than 5%.^{29,30} Hospitalized patients were more likely to be male, of Black,
168 Asian/Pacific Islander, American Indian, or Alaskan Native racial backgrounds, of Hispanic ethnicity, and
169 living in an area with a higher social vulnerability index (**Table 1**). Of the 36 individuals who were of
170 Black, Asian/Pacific Islander, American Indian, or Alaskan Native racial backgrounds or Hispanic

171 ethnicity, 42.4% were hospitalized. Sixty-four patients (38%) had COVID-19 in the period after
172 December 31, 2021 when Omicron accounted for the majority of infections in Massachusetts.

173 Humoral immunodeficiencies were the most common type of inborn error of immunity, followed
174 by combined immunodeficiencies (**Table 1**). Among inpatients, 64.5% had a genetically defined immune
175 disorder attributable to a genetic variant confirmed by clinical-grade DNA sequencing, compared to
176 34.1% of outpatients (**Table 1**). Organ dysfunction caused by recurrent infections and/or autoimmunity is
177 a complication of inborn errors of immunity that may be treated with B cell-depleting therapies.³¹
178 Inpatients were more likely to have organ dysfunction and B cell depleting therapies within one year prior
179 to infection, compared to outpatients. Among comorbidities known to be associated with severe COVID-
180 19,³² obesity, neurologic disease, chronic renal disease, and cardiovascular disease were the most
181 common and occurred more frequently in inpatients than outpatients (**Table 1**).

182

183 *Use of COVID-19 medical interventions*

184 FDA emergency authorization for COVID-19 vaccines was granted in December 2020, but
185 distribution was hampered by limitations in supply, logistics, and public trust.³³ The majority of inpatients
186 (74.2%) and outpatients (57.0%) were infected with SARS-CoV-2 before COVID-19 vaccination.
187 Additionally, 35 patients received post-exposure treatment with monoclonal antibodies SARS-CoV-2 as
188 they were asymptomatic but tested positive, in accordance with FDA recommendations, three of whom
189 required subsequent hospitalization due to worsening disease.

190

191 *Risk factors associated with hospitalization among patients with inborn errors of immunity*

192 Among demographic factors, Black, Asian/Pacific Islander, American Indian, or Alaskan Native
193 racial background and/or Hispanic ethnicity was significantly associated with an increased risk of
194 hospitalization (OR 5.29; CI, 1.75-17.0), while social vulnerability index was not. Older age was
195 associated with a marginally increased risk of hospitalization (OR 1.05; CI, 1.01-1.10). Hospitalization
196 was also associated with the following clinical features relevant to inborn errors of immunity: a history of

197 a genetically defined immunodeficiency (OR 4.62; CI, 1.60-14.8) and treatment with B cell depleting
198 agents within one year of infection (OR 6.10; CI, 1.05-38.5). Notably, neither defective T cell function
199 nor a history of immune-associated organ dysfunction was associated with an increased risk of
200 hospitalization. Among the comorbidities associated with severe COVID-19 in the general population,
201 obesity (OR 3.74; CI, 1.17 to 12.5) and a history of neurologic disease (OR 5.38; CI, 1.61 to 17.8), were
202 associated with increased risk of hospitalization. Infection after December 31, 2021, at which point the
203 Omicron variant accounted for over 95% of SARS-CoV-2 infections in Massachusetts, was not associated
204 with increased hospitalizations. With respect to SARS-CoV-2 interventions, an increased number of
205 COVID-19 vaccination doses was associated with reduced hospitalization risk (OR 0.52; CI, 0.31-0.81),
206 while treatment with SARS-CoV-2 monoclonal antibody was not statistically significant. A standard
207 logistic regression model identified the same risk factors with similar adjusted ORs (**Figure 2** and **Figure**
208 **E1**).

209

210 **Discussion**

211 Although inborn errors of immunity are rare diseases, they serve as real-world disease models
212 that enable delineation of specific pathways contributing to immunologic risk. While rare disease research
213 focuses on disease-specific principles toward a goal of personalized medicine, common risk factors for
214 disease can be overlooked. Prior studies have not assessed the contributions of race, ethnicity, or social
215 vulnerability to outcomes from SARS-CoV-2 infection in individuals with inborn errors of immunity.^{6,9-21}
216 Our study reveals the importance of contextualizing host immunity within common determinants of
217 health, which are significant contributors to outcomes from SARS-CoV-2 infections.

218 We found that obesity was associated with increased odds of hospitalization, concordant with
219 SARS-CoV-2 outcomes in the general pediatric and adult populations.^{34,35} Guidelines for clinical
220 management of inborn errors of immunity highlight low body weight as a predictor of immunologic
221 compromise.^{21,25} However, the prevalence of obesity in pediatric and adult patients with inborn errors of
222 immunity is now comparable to that of the general population.³⁶ During the H1N1 influenza pandemic,

223 obesity was also associated with increased morbidity and mortality in the general population.³⁷ Adipose
224 tissue can serve as a reservoir for viral replication, the priming of inflammatory myeloid and lymphoid
225 cells, and a source of inflammatory cytokines and adipokines.³⁸ Future studies are needed to determine
226 how obesity influences clinical outcomes other than SARS-CoV-2 infections in patients with inborn
227 errors of immunity.

228 Here, we show that underrepresented racial and ethnic groups, but not SVI, are associated with
229 increased odds of hospitalization. The lack of association between SVI and SARS-CoV-2-related
230 hospitalizations in our study may arise from the availability of medical coverage for children and
231 adolescents living in Massachusetts, which is the highest in the U.S.: only 1.2% of children in
232 Massachusetts are uninsured, compared to a national average of 5.2%.³⁹ Approximately one third of
233 children in Massachusetts receive healthcare through the state's Medicaid program providing school-
234 based medical care.³⁹ Additionally, this study was conducted at a tertiary medical center providing
235 immunology subspecialty care. However, the persistent disparities in healthcare are underscored by the
236 5.2-fold odds of hospitalization associated with Black, Black, Asian/Pacific Islander, American Indian, or
237 Alaskan Native race and/or Hispanic ethnicity in this study. This is concordant with studies in the general
238 pediatric population showing increased hospitalizations and deaths from SARS-CoV-2 infections among
239 non-Hispanic Black or Hispanic children compared to White children.^{40,41}

240 Race and ethnicity have inextricably been linked with disadvantages in SDOH for minority
241 groups when pertaining to specific conditions, including cardiovascular disease⁴² and diabetes.⁴³ With
242 regards to COVID-19, on a county level in the US there is association between adverse SDOH factors,
243 percent Black residents, and mortality rate. However, in counties with below average adverse SDOH
244 factors there was no association between percent Black residents and mortality, implying that racial
245 disparities are driven by social constructs.⁴⁴ Specific to the pediatric population, there are significant
246 racial and ethnic differences across all categories of SDOH, including economic stability, education
247 access and quality, health care access and quality, neighborhood and built environment, and social and
248 community context.⁴⁵ Interestingly, within our cohort race and ethnicity were associated with

249 hospitalizations independent of SVI, indicating that additional studies are needed to delineate how
250 underlying inequities and structural racism affect other outcomes in patients with inborn errors of
251 immunity.

252 Our findings identify a potential role for genetic sequencing in assessing immunologic risk. The
253 heterogenous clinical phenotypes of inborn errors of immunity complicate the diagnosis and management
254 of these disorders. Defining the underlying genetic etiology improves understanding of patient
255 phenotypes can guide directed therapies.¹ Despite the declining costs of genetic sequencing, genetic tests
256 are not routinely covered by most insurance companies.⁴⁶ Genetic diagnoses in our cohort were made
257 feasible by an institutional program that enables clinical whole exome sequencing at no cost to patients.⁴⁷
258 In our study, patients with a genetically defined immunodeficiency had 5.3-fold greater odds of
259 hospitalization. Within this group, there was no significant predilection among types of genetic defects:
260 there were similar numbers of hospitalized patients with combined defects and humoral defects, with
261 fewer patients with innate defects or PIRD (**Figure E2**). The reasons for hospitalization indicate that our
262 findings were not attributable to clinical monitoring of patients with genetic diagnoses (**Table 2**). Rather,
263 we posit that individuals with genetically confirmed immunodeficiencies have more severe immunologic
264 disease and thus, a higher risk of severe SARS-CoV-2 infections. This hypothesis is supported by
265 evidence showing that the likelihood of a genetic diagnosis is higher in patients with severe clinical
266 presentations.²¹ Disease severity was controlled in our analysis using organ dysfunction as a surrogate.
267 Notably, organ dysfunction – a standard measure of disease severity for disorders of immunity³¹ – was not
268 associated with increased hospitalization risk in our cohort, even though it was present in 45.2% of
269 inpatients and 34.1% of outpatients. Thus, genetic diagnoses may enable better identification of
270 individuals with increased immunologic risk. Identification of genetic disorders will be made possible
271 only through equitable access to genetic testing, a goal that remains elusive in the U.S. due to gaps in
272 clinician knowledge, limited and inconsistent insurance coverage of genetic tests, and the scarcity of
273 community-based or patient-centered educational resources in genomic medicine.⁴⁸

274 Although hospitalization was most frequent in those with innate immune defects or combined
275 immunodeficiencies, we did not find a significant association of defective T cell immunity with
276 hospitalization when controlling for covariates. This may be due, at least in part, to national newborn
277 screening programs for severe combined immunodeficiency that enable early diagnosis and treatment.⁴⁹
278 Thus, most children with the most severe combined immunodeficiencies will have undergone
279 hematopoietic stem cell transplantation before entry into daycare and school settings with potentially high
280 levels of viral transmission. We found that increasing numbers of COVID-19 vaccinations were
281 associated with a significantly reduced risk of hospitalization, further providing evidence that the school-
282 aged and older individuals in this cohort had partial retention of immune function. Similarly, the largest
283 study of mRNA vaccine efficacy in individuals with congenital immunodeficiencies found that the
284 majority of patients with combined immunodeficiencies mounted an intact vaccine-specific T cell
285 response.⁵⁰ Although impaired T cell function is a commonly used measure of susceptibility to viral
286 infections, our study highlights the limitations of applying this principle without acknowledgement of
287 other determinants for health. Genetic diagnoses, obesity, comorbid conditions, and race modulate the
288 immunologic risk often attributed solely to the mechanisms underlying congenital immunodeficiencies.

289 By using a multivariate regression model, we adjusted for variations in SARS-CoV-2 directed
290 interventions as some patients received vaccines and monoclonal antibodies while others did not. These
291 differences were largely due to the availability of these agents during time of infection and governmental
292 recommendations regarding eligibility. Similar models have been used to account for confounding factors
293 in COVID-19 studies.^{51,52} Furthermore, the single center design of our study minimized variability in
294 clinical practice. Patients with primary immunodeficiencies and SARS-CoV-2 infection were managed
295 using institution-approved guidelines and algorithms to standardize modalities of care.

296 Our study has limitations. This is a single center, retrospective study and inborn errors of
297 immunity are rare diseases. It is infeasible to definitively determine the total number of patients with
298 SARS-CoV-2 infections because SARS-CoV-2 test availability was limited at the start of the pandemic,
299 patients may not report all positive home antigen tests to healthcare providers, and asymptomatic SARS-

300 CoV-2 infections are underreported. Given the limitations inherent in studies of rare diseases with small
301 sample sizes, our study sought to determine the contributions of common risk factors that are often
302 overlooked in rare diseases due to the “N of 1” approach typical of personalized medicine.

303 The morbidity and mortality caused by the COVID-19 pandemic transformed immunologic risk
304 from an abstract concept into a real-world axis that influences daily decisions about school, work, and
305 travel. The findings of this study indicate the importance of considering factors beyond molecular
306 mechanisms as measures of immunologic risk and suggest that this risk can be modified by initiatives
307 pertaining to obesity and healthcare disparities.

308

309 **Acknowledgements**

310 This study was supported by the National Institutes of Health (T32AI007512 to H.C.O., A.A.N.,
311 B.L., D.H.; K23AI143962 to L.M.B., R01DK130465 and R01AI139633-04S1 to J.C.), the Wallace
312 Family Fund and Perkins Fund (to J.C.), and the Department of Pediatrics at King Abdulaziz University,
313 Jeddah, KSA (to S.B.H.).

314

315

316 **References**

- 317 1. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation of Scarce
318 Medical Resources in the Time of Covid-19. *N Engl J Med.* 2020;382(21):2049–55.
- 319 2. Lemmon ME, Truog RD, Ubel PA. Allocating Resources Across the Life Span During COVID-19—
320 Integrating Neonates and Children Into Crisis Standards of Care Protocols. *JAMA Pediatrics.*
321 2021;175(4):347–8.
- 322 3. Bledsoe TA, Jokela JA, Deep NN, Snyder Sulmasy L. Universal Do-Not-Resuscitate Orders, Social
323 Worth, and Life-Years: Opposing Discriminatory Approaches to the Allocation of Resources
324 During the COVID-19 Pandemic and Other Health System Catastrophes. *Ann Intern Med.*
325 2020;M20-1862.
- 326 4. Healthy People 2030 | health.gov.
- 327 5. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human
328 Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of
329 Immunological Societies Expert Committee. *J Clin Immunol.* 2022;42(7):1473–507.
- 330 6. Bucciol G, Tangye SG, Meyts I. Coronavirus disease 2019 in patients with inborn errors of
331 immunity: lessons learned. *Curr Opin Pediatr.* 2021;33(6):648–56.
- 332 7. Zhang Q, Bastard P, COVID Human Genetic Effort, Cobat A, Casanova J-L. Human genetic and
333 immunological determinants of critical COVID-19 pneumonia. *Nature.* 2022;603(7902):587–98.
- 334 8. Prioritization of Therapeutics. COVID-19 Treatment Guidelines.
- 335 9. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in
336 patients with inborn errors of immunity: An international study. *J Allergy Clin Immunol.*
337 2021;147(2):520–31.
- 338 10. Karakoc Aydinler E, Bilgic Eltan S, Babayeva R, Aydinler O, Kepenekli E, Kolukisa B, et al. Adverse
339 COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses. *Allergy.*
340 2022;77(1):282–95.

- 341 11. Castano-Jaramillo LM, Yamazaki-Nakashimada MA, O’Farrill-Romanillos PM, Muzquiz Zermeño
342 D, Scheffler Mendoza SC, Venegas Montoya E, et al. COVID-19 in the Context of Inborn Errors of
343 Immunity: a Case Series of 31 Patients from Mexico. *J Clin Immunol.* 2021;41(7):1463–78.
- 344 12. Esenboga S, Ocak M, Akarsu A, Bildik HN, Cagdas D, Iskit AT, et al. COVID-19 in Patients with
345 Primary Immunodeficiency. *J Clin Immunol.* 2021;41(7):1515–22.
- 346 13. Goudouris ES, Pinto-Mariz F, Mendonça LO, Aranda CS, Guimarães RR, Kokron C, et al. Outcome
347 of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional
348 Study. *J Clin Immunol.* 2021;41(7):1479–89.
- 349 14. Ho H, Mathew S, Peluso MJ, Cunningham-Rundles C. Clinical outcomes and features of COVID-19
350 in patients with primary immunodeficiencies in New York City. *J Allergy Clin Immunol Pract.*
351 2021;9(1):490-493.e2.
- 352 15. Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, et al. Minor Clinical Impact of
353 COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel. *Front Immunol.*
354 2020;11:614086.
- 355 16. Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical outcome,
356 incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of
357 immunity. *J Allergy Clin Immunol Pract.* 2021;9(7):2904-2906.e2.
- 358 17. Milota T, Sobotkova M, Smetanova J, Bloomfield M, Vydlakova J, Chovancova Z, et al. Risk
359 Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity -
360 Results From a Multicenter Nationwide Study. *Front Immunol.* 2022;13:835770.
- 361 18. Moazzen N, Ahanchian H, Aelami MH, Asiyon H, Astaneh M, Naeimi AM, et al. COVID-19 in
362 children with inborn errors of immunity: clinical scenarios. *Am J Clin Exp Immunol.*
363 2021;10(3):77–85.
- 364 19. Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients
365 with primary and secondary immunodeficiency: The United Kingdom experience. *J Allergy Clin*
366 *Immunol.* 2021;147(3):870-875.e1.
- 367 20. The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of
368 the Italian Primary Immunodeficiencies Network (IPINet) - PubMed.
- 369 21. Abolhassani H, Delavari S, Landegren N, Shokri S, Bastard P, Du L, et al. Genetic and immunologic
370 evaluation of children with inborn errors of immunity and severe or critical COVID-19. *J Allergy*
371 *Clin Immunol.* 2022;150(5):1059–73.
- 372 22. Cousins K, DeFelice N, Jeong S, Feng J, Lee ASE, Rotella K, et al. SARS-COV-2 infections in
373 inborn errors of immunity: A single center study. *Frontiers in Immunology.* 2022;13.
- 374 23. CDC/ATSDR Social Vulnerability Index (SVI). 2022.
- 375 24. Bureau UC. American Community Survey 2014-2018 5-Year Estimates Now Available. *Census.gov.*

- 376 25. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the
377 diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol*.
378 2015;136(5):1186-1205.e1-78.
- 379 26. Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in Regression Analyses
380 Conducted in Epidemiologic Studies. *Epidemiology (Sunnyvale)*. 2016;6(2):227.
- 381 27. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. 2020.
- 382 28. Firth D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika*. 1993;80(1):27–38.
- 383 29. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness duration and
384 symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. *The Lancet*
385 *Child & Adolescent Health*. 2021;5(10):708–18.
- 386 30. Forrest CB, Burrows EK, Mejias A, Razzaghi H, Christakis D, Jhaveri R, et al. Severity of Acute
387 COVID-19 in Children <18 Years Old March 2020 to December 2021. *Pediatrics*.
388 2022;149(4):e2021055765.
- 389 31. Delmonte OM, Castagnoli R, Calzoni E, Notarangelo LD. Inborn Errors of Immunity With Immune
390 Dysregulation: From Bench to Bedside. *Front Pediatr*. 2019;7:353.
- 391 32. People with Certain Medical Conditions. Centers for Disease Control and Prevention. 2023.
- 392 33. Jean-Jacques M, Bauchner H. Vaccine Distribution—Equity Left Behind? *JAMA*. 2021;325(9):829–
393 30.
- 394 34. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated
395 with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430–6.
- 396 35. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics
397 and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in
398 Children (MIS-C) Compared With Severe Acute COVID-19. *JAMA*. 2021;325(11):1074–87.
- 399 36. Ruffner MA, Sullivan KE. Complications associated with underweight primary immunodeficiency
400 patients: prevalence and associations within the USIDNET Registry. *J Clin Immunol*.
401 2018;38(3):283–93.
- 402 37. Van Kerkhove MD, Vandemaële KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly
403 CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global
404 pooled analysis. *PLoS Med*. 2011;8(7):e1001053.
- 405 38. Kanneganti T-D, Dixit VD. Immunological complications of obesity. *Nat Immunol*. 2012;13(8):707–
406 12.
- 407 39. The Number of Uninsured Children is on the Rise. Center For Children and Families. 2019.
- 408 40. Moreira A, Chorath K, Rajasekaran K, Burmeister F, Ahmed M, Moreira A. Demographic predictors
409 of hospitalization and mortality in US children with COVID-19. *Eur J Pediatr*. 2021;180(5):1659–
410 63.

- 411 41. Antoon JW, Grijalva CG, Thurm C, Richardson T, Spaulding AB, Teufel RJ, et al. Factors
412 Associated With COVID-19 Disease Severity in US Children and Adolescents. *J Hosp Med.*
413 2021;16(10):603–10.
- 414 42. Javed Z, Haisum Maqsood M, Yahya T, Amin Z, Acquah I, Valero-Elizondo J, et al. Race, Racism,
415 and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic
416 Disparities in Cardiovascular Disease. *Circ Cardiovasc Qual Outcomes.* 2022;15(1):e007917.
- 417 43. Walker RJ, Strom Williams J, Egede LE. Influence of Race, Ethnicity and Social Determinants of
418 Health on Diabetes Outcomes. *Am J Med Sci.* 2016;351(4):366–73.
- 419 44. Dalsania AK, Fastiggi MJ, Kahlam A, Shah R, Patel K, Shiao S, et al. The Relationship Between
420 Social Determinants of Health and Racial Disparities in COVID-19 Mortality. *J Racial Ethn Health*
421 *Disparities.* 2022;9(1):288–95.
- 422 45. Monroe P, Campbell JA, Harris M, Egede LE. Racial/ethnic differences in social determinants of
423 health and health outcomes among adolescents and youth ages 10–24 years old: a scoping review.
424 *BMC Public Health.* 2023;23(1):410.
- 425 46. Reuter CM, Kohler JN, Bonner D, Zastrow D, Fernandez L, Dries A, et al. Yield of whole exome
426 sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. *J Genet*
427 *Couns.* 2019;28(6):1107–18.
- 428 47. Rockowitz S, LeCompte N, Carmack M, Quitadamo A, Wang L, Park M, et al. Children’s rare
429 disease cohorts: an integrative research and clinical genomics initiative. *npj Genom Med.*
430 2020;5(1):1–12.
- 431 48. National Academies of Sciences E, Division H and M, Policy B on HS, Health R on G and P.
432 Introduction and Overview. In: *Understanding Disparities in Access to Genomic Medicine:*
433 *Proceedings of a Workshop.* National Academies Press (US); 2018.
- 434 49. Lankester AC, Albert MH, Booth C, Gennery AR, Güngör T, Hönig M, et al. EBMT/ESID inborn
435 errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of
436 immunity. *Bone Marrow Transplant.* 2021;56(9):2052–62.
- 437 50. van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al.
438 Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of
439 immunity. *J Allergy Clin Immunol.* 2022;149(6):1949–57.
- 440 51. Adir Y, Humbert M, Saliba W. COVID-19 risk and outcomes in adult asthmatic patients treated with
441 biologics or systemic corticosteroids: Nationwide real-world evidence. *J Allergy Clin Immunol.*
442 2021;148(2):361-367.e13.
- 443 52. Guan W-J, Liang W-H, Shi Y, Gan L-X, Wang H-B, He J-X, et al. Chronic Respiratory Diseases and
444 the Outcomes of COVID-19: A Nationwide Retrospective Cohort Study of 39,420 Cases. *J Allergy*
445 *Clin Immunol Pract.* 2021;9(7):2645-2655.e14.

446
447
448
449

450 **Figure Legends.**

451 **Figure 1. Summary of study design.** (A) Affected pathways implicated in the four main categories of
452 inborn errors of immunity. (B) Flow diagram of study participants.

453 **Figure 2. Adjusted risk of SARS-CoV-2-related hospitalization in individuals with inborn errors of**
454 **immunity.** Odds ratios and 95% confidence intervals (CI) for each respective determinant of health, as
455 calculated by logistic regression with covariate analysis. After December 31, 2021, the Omicron variant
456 accounted for at least 95% of SARS-CoV-2 infections.

457 **Figure E1. Secondary analysis of adjusted risk of SARS-CoV-2-related hospitalization in**
458 **individuals with inborn errors of immunity.** Odds ratios and 95% confidence intervals (CI) derived
459 from a standard logistic regression analysis model, after adjusting for all covariates listed. After
460 December 31, 2021, the Omicron variant (the first SARS-CoV-2 variant to have immune escape)
461 accounted for at least 95% of SARS-CoV-2 infections.

462 **Figure E2. Severity of SARS-CoV-2 infection in patients with genetically defined inborn errors of**
463 **immunity.** Monogenic inborn errors of immunity separated by severity of disease and categorized by
464 phenotypic classification.

Table 1. Patient characteristics.

	Hospitalized n = 31	Outpatient n = 135
Median age, years (range)	16.3 (0.5 – 51.7)	14.9 (0.2 – 68.8)
Age subgroups, n (%)		
0.2 – 5 years	6 (19.4)	18 (13.3)
5 – 12 years	8 (25.8)	36 (26.7)
12 – 18 years	6 (19.4)	37 (27.4)
18 – 29 years	8 (25.8)	29 (21.5)
29 – 69 years	3 (9.6)	15 (11.1)
Biologic sex, n (%)		
Male	18 (58.1)	73 (54.1)
Female	13 (41.9)	62 (45.9)
Self-reported race, n (%)		
Asian/Pacific Islander	2 (6.5)	2 (1.5)
Black	3 (9.7)	6 (4.4)
American Indian or Alaska Native	1 (3.2)	0
White	17 (54.8)	116 (86.0)
Other ^a	8 (25.8)	11 (8.1)
Self-reported ethnicity, n (%)		
Hispanic	8 (25.8)	8 (5.9)
Non-Hispanic	23 (74.2)	127 (94.1)
Median Social vulnerability index (range)	0.41 (0.10 – 0.88)	0.28 (0.018 – 0.97)
Subtypes of inborn errors of immunity, n (%)		
Humoral immune defects	12 (37.5)	83 (61.5)
Combined immune deficiency	11 (35.5)	30 (22.2)
Innate immune defect	3 (9.7)	4 (3.0)
Primary immune dysregulatory disorder	5 (16.1)	18 (13.3)
Clinical features and comorbidities, n (%)		
Genetically-defined inborn error of immunity	20 (64.5)	46 (34.1)
End-organ dysfunction	14 (45.2)	46 (34.1)
Rituximab treatment at time of infection	5 (16.1)	6 (4.4)
Obesity	10 (32.3)	22 (16.3)
Neurologic disease	8 (25.8)	16 (11.9)
Chronic renal disease	4 (12.9)	3 (2.2)
Cardiovascular disease	4 (12.9)	13 (9.6)
History of organ or stem cell transplantation	2 (6.5)	7 (5.2)
Malignancy	1 (3.2)	2 (1.5)
Chronic liver disease	1 (3.2)	6 (4.4)
Trisomy 21	1 (3.2)	3 (2.2)
COVID-19-related therapeutics n (%)		
Number of COVID-19 vaccine doses ^b		
0	24 (77.4)	77 (57.0)
1	3 (9.7)	1 (0.7)
2	2 (6.5)	31 (23.0)
3	2 (6.5)	26 (19.3)
Monoclonal antibodies against SARS-CoV-2 ^c	4 (12.9)	30 (23.0)

a. For self-reported race, “other” denotes those patients who selected “other” as their racial background

b. All COVID-19 vaccines were given prior to April 2022, which excluded the bivalent formulations

c. Monoclonal antibodies included sotrovimab, bamlanivimab, casirivimab, imdevimab, and tixagevimab/cilgavimab

Table 2. Reasons for hospitalization*.

Cause	Number (%)
Respiratory instability	13 (42)
Hemodynamic instability	3 (10)
Worsening immune dysregulation	4 (13)
Fever and neutropenia	2 (6)
Severe gastrointestinal symptoms	4 (13)
Multisystem Inflammatory Syndrome in Children	3 (10)
Clinical monitoring due to clinician concern	2 (6)

*See Methods for information about category designation

Figure 1.




Figure 2.

